Bavarian Nordic’s Mpox vaccine met with the World Health Organization's approval on Monday for use among adolescents aged between 12-17. This age bracket is considered to be highly vulnerable to ...

Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group to contain an ...

The first mpox vaccine approved by the WHO is MVA-BN, made by Bavarian Nordic A/S. It was approved for emergency use and can be used "off-label" in infants, children and adolescents as well as in ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness ...

The World Health Organization says it has cleared Bavarian Nordic's mpox vaccine, the first such vaccine to be approved by the agency for containing the spread of the disease in badly hit African ...

A clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to a planned interim analysis of study data.

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up ...

Key takeaways: Jynneos was safe and generated an antibody response in adolescents that was similar to that seen in adults. The new data could help expand the number of people eligible for the vaccine.

F.D.A. Approves Novavax Covid Vaccine With Stricter New Conditions The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions. Listen to ...

A National Institutes of Health (NIH)-funded clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to a ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...